[go: up one dir, main page]

WO2011130429A9 - Methods and materials for treating lung cancer - Google Patents

Methods and materials for treating lung cancer Download PDF

Info

Publication number
WO2011130429A9
WO2011130429A9 PCT/US2011/032350 US2011032350W WO2011130429A9 WO 2011130429 A9 WO2011130429 A9 WO 2011130429A9 US 2011032350 W US2011032350 W US 2011032350W WO 2011130429 A9 WO2011130429 A9 WO 2011130429A9
Authority
WO
WIPO (PCT)
Prior art keywords
materials
methods
lung cancer
treating lung
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/032350
Other languages
French (fr)
Other versions
WO2011130429A2 (en
Inventor
Alan P. Fields
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of WO2011130429A2 publication Critical patent/WO2011130429A2/en
Publication of WO2011130429A9 publication Critical patent/WO2011130429A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/30Copper compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2011/032350 2010-04-13 2011-04-13 Methods and materials for treating lung cancer Ceased WO2011130429A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32373710P 2010-04-13 2010-04-13
US61/323,737 2010-04-13

Publications (2)

Publication Number Publication Date
WO2011130429A2 WO2011130429A2 (en) 2011-10-20
WO2011130429A9 true WO2011130429A9 (en) 2012-02-23

Family

ID=44799300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/032350 Ceased WO2011130429A2 (en) 2010-04-13 2011-04-13 Methods and materials for treating lung cancer

Country Status (1)

Country Link
WO (1) WO2011130429A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
EP3052655B1 (en) * 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed

Also Published As

Publication number Publication date
WO2011130429A2 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
EP2542585B8 (en) Methods for treating colorectal cancer
EP2655309A4 (en) Methods and compositions for treating lung cancer
EP2542584B8 (en) Methods for treating pancreatic cancer
EP2649391B8 (en) Drying apparatus and methods
EP2549963A4 (en) Systems and methods for prostate treatment
WO2011140517A9 (en) Methods for treating diseases of the lung
WO2012009611A9 (en) Methods and compositions for cancer immunotherapy
IL223295A0 (en) Lung cancer biomarkers and uses thereof
IL231426A (en) Lung cancer biomarkers and uses thereof
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2564200B8 (en) Cancer biomarkers and methods of use thereof
WO2012061413A3 (en) Isoflavonoid compositions and methods for the treatment of cancer
WO2012018877A9 (en) Treating breast cancer with anti-il-19 antibody
EP2590712A4 (en) System and method for hyperthermic tumor treatment
WO2012030896A9 (en) Methods for treatment of non-small cell lung cancer
EP2593111A4 (en) New compounds for treating cancer and other diseases
WO2011130429A9 (en) Methods and materials for treating lung cancer
EP2537031A4 (en) Compositions and methods for treating cancer
WO2012061820A9 (en) Materials and methods for treating radiation poisoning
AU2016202538A1 (en) Reagents and methods for treating cancer
HK1255654A (en) Compositions and methods for treating myelofibrosis
HK1189268A (en) Methods of treating cancer
HK1189267A (en) Methods of treating cancer
HK1191599A (en) Compositions and methods for treating cancer
AU2011211693B2 (en) Pharmaceutical composition for treating and/or preventing cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11769538

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11769538

Country of ref document: EP

Kind code of ref document: A2